帕金森病的认知障碍:更新的概述,重点关注新兴的药物治疗方法
Yildiz Degirmenci1,2, Efthalia Angelopoulou3, Vasiliki Epameinondas Georgakopoulou4
1Department of Neurology, School of Medicine, Istanbul Health and Technology University, 34093 Istanbul, Turkey.
Medicina (Kaunas, Lithuania)
|October 28, 2023
概括
认知障碍在帕金森病 (PD) 中很常见,影响生活质量. 新兴的治疗方法通过准a-synuclein聚合和神经炎症等机制,显示出有前途.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 认知障碍是帕金森病 (PD) 的常见和致残的非运动症状.
- 范围从主观认知衰退到帕金森病痴呆症 (PDD),显著影响患者和护理人员.
- 目前的治疗方法有效性有限,无法阻止疾病的进展,因此需要新的治疗策略.
研究的目的:
- 审查帕金森病中认知障碍的临床谱.
- 讨论新兴的治疗药物及其与PD相关的认知障碍的潜在机制.
- 为有效的干预提出未来研究方向的建议.
主要方法:
- 对PD认知障碍新兴治疗方法的临床前和临床证据的文献综述.
- 分析潜在的治疗机制,包括a-synuclein抑制,线粒体功能,神经炎症和神经传递.
- 综合当前数据,为未来的研究方向提供信息.
主要成果:
- 许多药物 (例如, ceftriaxone,ambroxol,鼻内胰岛素) 在临床前和临床研究中显示出潜在的益处.
- 作用机制包括a-synuclein聚合抑制,改善线粒体功能,神经炎症调节和神经递质系统调节.
- 目前正在研究一系列新的治疗策略.
结论:
- 针对多种途径的新兴治疗方法为管理帕金森病的认知障碍提供了潜力.
- 进一步的研究至关重要,以验证这些药物,并制定有效的策略,PD相关的认知衰退.
- 了解多方面的机制是推进治疗选择的关键.
相关概念视频
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Psychosis: Goals of Pharmacotherapy
145
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
145
Drug Therapy
47
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
47


